©The Author(s) 2025.
World J Clin Oncol. Nov 24, 2025; 16(11): 111627
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111627
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111627
Figure 10 Drug sensitivity analysis.
A: Drug-sensitivity profiling of ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6) was conducted online using the Gene Set Cancer Analysis platform; B-G: Molecular docking results of ENTPD6 protein with SB590885, selumetinib, RDEA119, PD-0325901, dabrafenib, and trametinib. Silvery white represents ENTPD6 protein, blue represents amino acid residue, yellow represents hydrogen atoms, and magenta represents drugs. GDSC: Genomics of Drug Sensitivity in Cancer; ENTPD6: Ectonucleoside triphosphate diphosphohydrolase 6; FDR: False discovery rate.
- Citation: Wang G, Liu T, Zhang JX, Li YR, Zhu WJ, Wang JL, Dong WW, Zhang YY, Li YM, Yang LX, He LX, He WT. Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6. World J Clin Oncol 2025; 16(11): 111627
- URL: https://www.wjgnet.com/2218-4333/full/v16/i11/111627.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i11.111627